Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06679829 · ClinicalTrials.gov registry record · Phase 2

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

A Phase 2 study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
215
Enrollment target
7
Study locations

NCT06679829: Recruiting Phase 2 study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT06679829 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 215 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (61% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06679829, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
215 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area \[BSA\]-dosed melphalan) in people with multiple myeloma (MM) who are receiving an autologous stem cell transplant (ASCT) as part of their standard treatment. The researchers will also see if siltuximab in combination with population PK-dosed melphalan works to decrease symptoms after an ASCT, and will study the safety of siltuximab. For the run-in, 15 patients will receive siltuximab, 11 mg/kg, seven days before and 14 days after autologous hematopoietic stem cell infusion (+/-2 day).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Melphalan
  • DRUG Siltuximab

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 215 participants
Start Date 2024-11-06
Est. Completion 2027-11
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06679829

The ClinicalTrials.gov registry entry for NCT06679829 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (61% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Melphalan is the first listed.

NCT06679829 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06679829 about?

NCT06679829 is a clinical study titled "A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant". The purpose of this study is to see if siltuximab plus population pharmacokinetic (PK)-dosed melphalan works as well as the usual approach (body surface area \[BSA\]-dosed melphalan) in people with multiple myeloma (MM) who are receiving an autologous stem cell transplant (ASCT) as part of their sta...

What is the current status of trial NCT06679829?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2024-11-06. Estimated completion is 2027-11.

What conditions does trial NCT06679829 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06679829?

The interventions under investigation include: Melphalan (DRUG), Siltuximab (DRUG).

Who is sponsoring clinical trial NCT06679829?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06679829 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.